alpha-aminopyridine has been researched along with Carcinoma, Non-Small Cell Lung in 145 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 63 (43.45) | 24.3611 |
| 2020's | 82 (56.55) | 2.80 |
| Authors | Studies |
|---|---|
| Bauer, TM; Calella, AM; de Marinis, F; Felip, E; Goto, Y; Kim, DW; Liu, G; Mazieres, J; Mok, T; Peltz, G; Polli, A; Shaw, AT; Solomon, BJ; Thurm, H | 2 |
| Akai, M; Demura, Y; Ishizuka, T; Jikuya, N; Kurokawa, K; Nakashima, K; Oi, M; Tada, T; Takeda, T | 1 |
| Daga, H; Ebi, N; Fukuhara, T; Furuya, N; Goto, K; Hayashi, K; Hayashida, T; Ikeda, T; Ishii, G; Izumi, H; Kato, T; Kirita, K; Kobayashi, SS; Kodani, M; Kumagai, S; Kuyama, S; Liu, J; Matsumoto, S; Mori, S; Nakachi, I; Nakai, T; Nakamura, A; Niho, S; Nishino, K; Nosaki, K; Ohtsu, A; Okamoto, I; Sakai, T; Sakakibara-Konishi, J; Shibata, Y; Sugiyama, E; Taima, K; Tanaka, K; Udagawa, H; Watanabe, K; Yamasaki, A; Yoh, K; Zenke, Y | 1 |
| Chang, XS; Chen, YD; Ding, KL; Liu, YF; Liu, YH; Ma, HC; Xiao, ZZ; Yu, YY; Zhang, HB; Zhao, WJ; Zhou, R; Zhu, YJ | 1 |
| Canas, GC; Ginman, K; Gong, J; LaBadie, RR; Lin, S; Pelletier, K; Pithavala, YK; Winkle, P | 1 |
| Abbattista, A; Bearz, A; Besse, B; Gadgeel, SM; Ou, SI; Shaw, AT; Solomon, BJ; Soo, RA; Toffalorio, F; Wiltshire, R | 1 |
| Bauer, TM; Bertino, EM | 1 |
| Avrillon, V; Baldacci, S; Bennouna, J; Besse, B; Bouledrak, K; Cadranel, J; Coudurier, M; Duruisseaux, M; Egenod, T; Galland-Girodet, S; Girard, N; Lamy, R; Missy, P; Moro-Sibilot, D; Odier, L; Otto, J; Prevost, A; Ricordel, C; Roch, B; Tillon-Strozyk, J; Westeel, V; Zalcman, G | 1 |
| Ahle, G; Arrondeau, J; Cortot, A; De Crozals, F; Duflot-Boukobza, A; Fallet, V; Lena, H; Naltet, C; Rouby, P | 1 |
| Avrillon, V; Baldacci, S; Besse, B; Cadranel, J; Clément-Duchêne, C; Cortot, AB; Cousin, S; Descourt, R; Doubre, H; Dubray-Longeras, P; Duruisseaux, M; Girard, N; Langlais, A; Mazieres, J; Mennecier, B; Merle, P; Monnet, I; Morin, F; Moro-Sibilot, D; Otto, J; Quantin, X; Ricordel, C; Schneider, S; Westeel, V | 1 |
| Abdelhady, A; Ardizzoni, A; Barlesi, F; Ch Yang, J; Chen, X; DiDominick, S; Felip, E; Hyoung Kang, J; Navarro, A; Santoro, A; Simonelli, M; Stammberger, U; Su, WC | 1 |
| Bai, C; Chang, J; Chen, G; Cheng, Y; Cui, J; Du, Y; Fan, Y; Fang, J; Huang, C; Li, H; Li, J; Liu, X; Liu, Z; Lu, S; Lu, Y; Pan, H; Peltz, G; Song, Y; Wang, K; Wu, YL; Yang, N; Zhang, H; Zhang, K; Zhao, H; Zhou, J; Zhou, Q | 1 |
| Guo, M; He, Z; Jin, C; Li, C; Liu, S; Qiu, J; Wang, Y; Wu, D | 1 |
| Chen, J; Martini, JF; Pithavala, YK; Sun, S | 1 |
| Gon, Y; Hiranuma, H; Nakagawa, Y; Shimizu, T | 1 |
| Ratain, MJ; Strohbehn, GW | 1 |
| Dagogo-Jack, I; Digumarthy, SR; Evangelist, M; Gainor, JF; Heist, RS; Lin, JJ; Murphy, JF; Muzikansky, A; Oxnard, GR; Rabin, MS; Shaw, AT | 1 |
| Abbattista, A; Hayashi, H; Hooi Wong, C; Huat Tan, E; Kim, DW; Lin, CC; Liu, G; Martini, JF; Ou, SI; Seto, T; Solomon, BJ; Soo, RA; Toffalorio, F | 1 |
| Pérol, M; Swalduz, A | 1 |
| Basse, C; Pasquier, C | 1 |
| Acker, A; Barth, JL; Dagogo-Jack, I; Dionne, K; Do, A; Gainor, JF; Hata, AN; Johnson, TR; Johnson, TW; Kiedrowski, LA; Lin, JJ; McTigue, MA; Mino-Kenudson, M; Nguyen-Phuong, L; Peterson, JL; Shiba-Ishii, A; Walcott, MA; Wei, P; Weinrich, SL; Yeap, BY; Yoda, S | 1 |
| Baba, K; Goto, Y | 1 |
| Baker, S; Blanchard, E; Brahmer, JR; Celano, P; Duma, N; Elkins, IB; Ellis, PM; Haddad, RY; Hesketh, PJ; Jain, D; Jaiyesimi, IA; Johnson, DH; Leighl, NB; Mamdani, H; Masters, G; Moffitt, PR; Phillips, T; Riely, GJ; Robinson, AG; Rosell, R; Schiller, JH; Schneider, BJ; Singh, N; Spigel, DR; Temin, S | 1 |
| Du, D; Ji, J; Ma, H; Qiu, Y; Xie, B; Zhang, W; Zhou, J; Zhu, L | 1 |
| Kashizaki, F; Sekido, Y; Tanaka, A | 1 |
| Fan, Y; Hong, Z; Jia, F; Li, G; Li, J; Li, Y; Liu, Z; Lu, S; Lu, Y; Wu, YL; Zhou, J; Zhou, Q | 1 |
| Ma, W; Zhao, B | 1 |
| Bosch-Barrera, J; Cuyàs, E; Encinar, JA; Fernández-Arroyo, S; Joven, J; Menendez, JA; Verdura, S | 1 |
| Akagi, K; Dotsu, Y; Gyotoku, H; Imamura, E; Mukae, H; Ono, S; Sen, T; Takemoto, S; Taniguchi, H; Yamada, T; Yamaguchi, H; Yano, S | 1 |
| Falk, M; Griesinger, F; Heukamp, LC; Hövel, I; Jóri, B; Tiemann, M; Weist, P | 1 |
| Abbattista, A; Dagogo-Jack, I; Do, A; Gainor, JF; Krueger, EA; Krulewicz, S; Lin, JJ; Messina, R; Murphy, JF; Peterson, J; Thurm, H; Yeap, BY | 1 |
| Liu, Q; Luo, X; Peng, L; Zeng, X; Zhou, Z | 1 |
| Acker, A; Besse, B; Camidge, DR; Davare, MA; Drilon, A; Gadgeel, SM; Hata, AN; Horan, JC; Keddy, C; Kohl, NE; Lin, JJ; Mente, S; Nguyen-Phuong, L; Nicholson, KS; Ou, SI; Pelish, HE; Porter, JR; Shair, MD; Soglia, JR; Sun, Y; Tangpeerachaikul, A; van der Wekken, AJ; Yoda, S; Zhu, V | 1 |
| Gainor, JF; Lin, JJ | 1 |
| Planchard, D; Riudavets, M | 1 |
| Ma, W; Wu, J; Zhao, B | 1 |
| Chahine, C; Felefly, T; Ibrahim, R; Khalife, N; Saleh, K | 1 |
| Berko, ER; Casey, C; Daniels, A; Gerelus, M; Ghazarian, S; Goldsmith, KC; Gostuski, I; Kalna, J; Kennedy, A; Krytska, K; Lemmon, MA; Marachelian, A; Maris, JM; Matkar, S; Mossé, YP; Park, JR; Pavlick, D; Petrova, ZO; Radhakrishnan, R; Smith, CM; Witek, GM; Wu, MA | 1 |
| Bauer, TM; Felip, E; Goto, Y; Iadeluca, L; Jassem, J; K Mok, TS; Kim, DW; Liu, G; López, FL; Marinis, F; Mazieres, J; Messina, R; Polli, A; Shaw, AT; Solomon, BJ; Soo, RA; Toffalorio, F; Wu, YL | 1 |
| Fujita, N; Gong, B; Hanzawa, H; Hata, AN; Isoyama, T; Iwasaki, S; Kagoshima, Y; Kamai, Y; Katayama, R; Kiga, M; Koike, S; Miyamoto, M; Nakao, N; Nishio, M; Oh-Hara, T; Seto, Y; Shaw, AT; Shimizu, Y; Takeda, Y; Togashi, N; Tominaga, Y; Watanabe, K; Yanagitani, N; Yoda, S | 1 |
| Barlesi, F; Besse, B; Demedts, I; Frimodt-Moller, B; Fuentes Pradera, J; Gazzah, A; Kim, JS; Robinet, G; Soldatenkova, V; Vansteenkiste, J | 1 |
| Camidge, DR; Patil, T | 1 |
| Agustoni, F; Arosio, G; Bidoli, P; Bisson, WH; Cordani, N; Cortinovis, D; Gambacorti-Passerini, C; Mologni, L; Pagni, F; Piazza, R; Sharma, GG; Villa, M | 1 |
| Abbattista, A; Bauer, TM; Besse, B; Chiari, R; Clancy, JS; Kao, S; Li, S; Lin, CC; Martini, JF; Ou, SI; Peltz, G; Riely, GJ; Shaw, AT; Solomon, BJ; Soo, RA; Thurm, H | 1 |
| Duruisseaux, M | 1 |
| Killock, D | 1 |
| Bergeron, M; Chen, J; Ginman, K; James, LP; Lee, K; Pawlak, S; Peltz, G; Pithavala, YK; Xu, H | 1 |
| Fujita, N; Horiike, A; Katayama, R; Kitazono, S; Koike, S; Nishikawa, S; Nishio, M; Ohyanagi, F; Tambo, Y; Tsukahara, M; Uchibori, K; Yanagitani, N; Yoshizawa, T | 1 |
| Dejust, S; El Farsaoui, K; Morland, D; Moubtakir, A; Prevost, A | 1 |
| Abbattista, A; Bauer, TM; Felip, E; Gainor, JF; Johnson, ML; Navarro, A; Peltz, G; Pithavala, YK; Shaw, AT; Thurm, H | 1 |
| Asokan, P; Atal, S; Jhaj, R | 1 |
| Choo, JR; Soo, RA | 1 |
| Jiang, W; Lizaso, A; Mao, X; Mi, J; Song, L; Yang, N; Zeng, L; Zhang, Y; Zhou, Y | 1 |
| Abbattista, A; Bearz, A; Besse, B; Clancy, JS; Felip, E; Gadgeel, SM; Kao, S; Lin, CC; Masters, ET; Peltz, G; Peters, S; Reisman, A; Ross Camidge, D; Seto, T; Shaw, AT; Solomon, BJ; Soo, RA; Thurm, H | 1 |
| Ge, Y; Kukreja, G; Nagasaka, M; Ou, SI; Sukari, A | 1 |
| Abdel-Rahman, O; El Darsa, H; Sangha, R | 1 |
| Pan, D; Yan, J; Zhou, X | 1 |
| Fukuhara, K; Goto, Y; Hayashi, H; Hida, T; Morise, M; Nagasawa, T; Niho, S; Nishio, M; Nogami, N; Ohkura, M; Peltz, G; Sakakibara-Konishi, J; Satouchi, M; Seto, T; Suzuki, M; Takahashi, T; Thurm, H | 1 |
| Guo, L; Jin, H; Lu, L; Sun, P; Yang, X; Yang, Y; Zhang, N; Zhao, Q; Zhou, L | 1 |
| Lee, CS; Seetharamu, N; Wanchoo, R | 1 |
| Feng, X; Xu, ES | 1 |
| Fujiwara, Y; Naito, T; Shiraishi, H | 1 |
| Eisenstein, M | 1 |
| Chen, J; Houk, B; Pithavala, YK; Ruiz-Garcia, A | 1 |
| Arai, Y; Hayashi, T; Kondo, A; Ninomiya, H; Shukuya, T; Suzuki, M; Takahashi, K; Takeshige, T; Ueda, S | 1 |
| Abbattista, A; Bauer, TM; Bauman, JR; Bearz, A; Besse, B; Camidge, DR; Felip, E; Peltz, G; Peters, S; Shaw, AT; Solomon, BJ; Thurm, H; Toffalorio, F; Wiltshire, R | 1 |
| Stinchcombe, TE | 1 |
| Camidge, DR | 1 |
| Nagasaka, M; Ou, SI | 1 |
| Akhter, N; Kanwar, YS; McGee, K; Stone, NJ; Villaflor, V; Wadhwani, S | 1 |
| Chaudhari, K; Nathany, S; Suryavanshi, M; Talwar, V | 1 |
| Chen, J; Gong, J; LaBadie, RR; Li, J; Mfopou, JK; Pithavala, YK | 1 |
| Chen, J; James, LP; Klamerus, KJ; Mugundu, G; O'Gorman, MT; Pithavala, YK | 1 |
| Chen, J; Clancy, J; Hibma, J; James, LP; Peltz, G; Ruiz-Garcia, A; Thurm, H | 1 |
| Biddle, KE; Chen, J; Finkelstein, M; Hu, W; Johnson, TR; Lettiere, D; Palazzi, X; Pithavala, YK; Thibault, S; Tse, S | 1 |
| Li, H; Sun, Y; Wang, J; Xu, X | 1 |
| Almond, C; Asanin, ST; Cooper, M; Iadeluca, L; Masters, ET; Nilsson, FOL; Smith, S | 1 |
| Aguiar, C; Barata, F; Hespanhol, V; Marques, JB; Marques, TR | 1 |
| Dunst, J; Richter, J | 1 |
| Li, B; Li, Q; Liu, L; Sheng, Z; Song, J; Teng, L; Wang, B; Wang, L; Zhang, J | 1 |
| Fukushima, T; Kanda, S; Kobayashi, T; Koizumi, T; Noguchi, T; Sekiguchi, N | 1 |
| Gong, ML; Qu, GP; Shi, M; Wang, D; Wang, P; Wu, JH; Zhang, ZJ | 1 |
| Chang, GC; Chen, KC; Hsu, KH; Huang, YH; Lee, PH; Tseng, JS; Yang, TY | 1 |
| Ginman, K; James, LP; Nepal, S; O'Gorman, MT; Pithavala, YK; Xu, H | 1 |
| Bannas, P; Beumer, N; Bokemeyer, C; Goekkurt, E; Iglauer, P; Imbusch, CD; Loges, S; Simon, R; Velthaus, JL | 1 |
| Chiang, CL; Chiang, TS; Chiu, CH; Chung, HP; Hung, JY; Ku, WH; Lee, KY; Lee, MH; Lin, CB; Lin, YT; Shih, JY; Su, J; Su, WC; Tseng, YH; Wei, YF; Wu, SY | 1 |
| Besse, B; Bria, E; Facchinetti, F; Friboulet, L; Minari, R; Rossi, G; Soria, JC; Tiseo, M | 1 |
| Chow, LQM; Crino, L; De Pas, T; Felip, E; Mok, TSK; Salgia, R; Tan, DSW | 1 |
| Ashraf, Z; Basit, S; Latif, M; Lee, K | 1 |
| Bayo, J; Behrens, C; Bhanu, NV; Coombes, K; Dalvi, MP; Garcia, BA; Gazdar, AF; Girard, L; Heymach, JV; Kalhor, N; Kittler, R; Kollipara, RK; Martinez, ED; Minna, JD; Mino, B; Park, H; Parra, ER; Pataer, A; Rodriguez-Canales, J; Suraokar, M; Swisher, SG; Timmons, BC; Villalobos, P; Wang, L; Wistuba, II; Xie, Y; Yenerall, P; Zhong, R; Zhou, Y | 1 |
| Ai, J; Chen, H; Chen, X; Gao, Y; Geng, M; He, Y; Li, C; Liu, H; Peng, X; Wang, J; Wang, Y; Zheng, M; Zhu, W | 1 |
| Kang, MJ; Lee, JH; Yun, HH | 1 |
| Wan, S; Wang, Y; Wu, X; Zhang, J | 1 |
| Hayashi, S; Hibino, Y; Kitada, M; Minami, Y; Miyokawa, N; Ohsaki, Y; Okumura, S; Sado, M; Sasaki, T; Yoshida, R | 1 |
| Abbattista, A; Bauer, TM; Besse, B; Chen, J; Clancy, JS; Dietrich, J; Felip, E; Gainor, JF; James, LP; Johnson, M; Martini, JF; Navarro, A; Postel-Vinay, S; Shaw, AT; Solomon, BJ | 1 |
| Catherinot, E; Chabrol, A; Chaumais, MC; Couderc, LJ; Doubre, H; Fraboulet, S; Friard, S; Hamid, AM; Mayenga, M; Metivier, AC; Montani, D; Rivaud, E; Salvator, H; Tcherakian, C | 1 |
| Chen, XM; Tu, SS; Zhang, FB; Zhao, C; Zheng, CH | 1 |
| Desai, A; Gadgeel, SM; Lisak, RP; Sriwastava, S | 1 |
| Balestra, V; Bordi, P; Facchinetti, F; Gnetti, L; Majori, M; Silini, EM; Silva, M; Tiseo, M; Ventura, L | 1 |
| Elkon, JM; Millett, RL; Tabbara, IA | 1 |
| Abbattista, A; Bauer, TM; Bearz, A; Besse, B; Camidge, DR; Chen, J; Chiari, R; Clancy, JS; Felip, E; Gadgeel, SM; James, LP; Lin, CC; Martini, JF; Ou, SI; Peltz, G; Riely, GJ; Seto, T; Shaw, AT; Solomon, BJ; Soo, RA; Tan, EH; Thurm, H | 1 |
| Morgensztern, D; Waqar, SN | 1 |
| Camidge, DR; Honce, JM; Lindquist, DL; Sakamoto, MR | 1 |
| Syed, YY | 1 |
| Gong, W; Yang, J | 1 |
| Araki, M; Fujita, N; Horiike, A; Ishikawa, T; Kanada, R; Katayama, R; Koike, S; Ma, B; Maemondo, M; Nishio, M; Oh-Hara, T; Okada, K; Okuno, Y; Sakashita, T; Tamai, K; Watanabe, K; Yanagitani, N | 1 |
| Chang, HY; Chien, PJ; Ko, JL; Ou, CC; Wang, BY; Wu, YF | 1 |
| Ahn, JS; Ahn, MJ; Choi, Y; Lee, J; Lee, SH; Park, K; Sun, JM | 1 |
| Ekman, S; Hydbring, P; Jatta, K; Kacal, M; Kanony, M; Kis, L; Lai, Y; Lewensohn, R; Norberg, E; Stukan, I; Vakifahmetoglu-Norberg, H | 1 |
| Akamine, T; Mori, M; Seto, T; Tagawa, T; Takeo, S; Toyokawa, G; Yamazaki, K | 1 |
| Bauer, TM; Chioda, MD; Felip, E; Peltz, G; Shaw, AT; Solomon, BJ; Thurm, H | 1 |
| Abbattista, A; Bauer, TM; Besse, B; Camidge, DR; Chiari, R; Clancy, JS; Felip, E; Gadgeel, SM; Kao, S; Li, S; Lin, CC; Martini, JF; Ou, SI; Riely, GJ; Satouchi, M; Shaw, AT; Solomon, BJ; Soo, RA; Thurm, H | 1 |
| Bao, X; Lu, S; Niu, X; Wang, M; Wang, Q; Wang, S; Wang, Y; Xu, L; Zhang, J | 1 |
| Bai, Y; Deng, L; Ding, M; Lu, D; Shao, YW; Wu, X; Yang, Y; Yu, R | 1 |
| Bradley, KM; Campo, L; Fenwick, JD; Gleeson, FV; Green, M; Higgins, GS; Horne, A; Macpherson, RE; Maughan, TS; McCole, MG; McGowan, DR; McKenna, WG; Mohammed, S; Muschel, RJ; Ng, SM; Panakis, N; Prevo, R; Skwarski, M; Strauss, VY; Stuart, R; Tacconi, EMC; Vallis, KA | 1 |
| Buffoni, L; Pellerino, A; Rudà, R; Soffietti, R | 1 |
| Chiba, S; Goto, K; Hatanaka, Y; Ikezawa, Y; Kitai, H; Matsumoto, S; Mizugaki, H; Sakakibara-Konishi, J; Sasaki, T; Shinagawa, N; Yoshida, R | 1 |
| Compter, A; de Waard, Q; Gafer, H; van den Heuvel, M | 1 |
| Alarcon, S; Collins, J; Doroshow, JH; Kinders, RJ; Kummar, S; Lee, MJ; Park, SR; Pfister, T; Piekarz, R; Speranza, G; Steinberg, SM; Trepel, JB; Wang, L; Wright, JJ | 1 |
| Chen, M; Deng, X; Khuri, FR; Li, Y; Owonikoko, TK; Ren, H; Sun, SY; Yue, P; Zhao, L | 1 |
| Nakagawa, T; Yano, S | 1 |
| Axel, U; Baska, F; Greff, Z; Gyulavári, P; Ibolya, K; Kéri, G; Orfi, L; Peták, I; Szántai, KC; Szokol, B; Vantus, T; Zoltán, O | 1 |
| Lu, XP; Nie, LP; Ning, ZQ; Pan, DS; Shan, S; Wan, J; Yue, XP; Zhang, K; Zhang, W; Zhou, Y; Zhu, JZ | 1 |
| Chen, L; Cress, WD; Kurtyka, CA | 1 |
| Lam, JL; Smeal, T; Vicini, P; Wang, H; Yamazaki, S; Zou, HY | 1 |
| Bryan, MC; Burdick, DJ; Chan, BK; Chen, Y; Dotson, J; Eigenbrot, C; Hanan, EJ; Heald, RA; Heffron, TP; Jackson, PS; La, H; Lainchbury, MD; Malek, S; Purkey, HE; Schaefer, G; Schmidt, S; Seward, EM; Sideris, S; Tam, C; Wang, S; Yeap, SK; Yen, I; Yin, J; Yu, C; Zilberleyb, I | 1 |
| Du, J; Liu, Q; Ni, Y; Pang, Z; Wang, L; Zhang, J | 1 |
| Aimone, P; Canon, JL; De Braud, F; De Pas, T; Di Tomaso, E; Dy, GK; Felip, E; Gray, JE; Gridelli, C; Grossi, F; Reck, M; Roussou, P; Soria, JC; Su, WC; Thongprasert, S; Vansteenkiste, JF; Vidam, GA; Wang, YA; Yoshioka, H | 1 |
| Ichinose, Y; Seto, T; Takenoyama, M; Toyokawa, G | 1 |
| Goldman, JW; Hurt, KC; Koustenis, A; Paz-Ares, L; Reck, M; Shi, P | 1 |
| Bergqvist, S; Brooun, A; Burke, BJ; Dardaei, L; Deng, YL; Engelman, JA; Frias, RL; Friboulet, L; Gainor, JF; Getz, G; Iafrate, AJ; James, LP; Johnson, TW; Katayama, R; Le, L; Leshchiner, I; Liu, W; Logan, J; McTigue, M; Schultz, KR; Shaw, AT; Smeal, T; Timofeevski, S | 1 |
| Liu, D; Savooji, J; Wu, J | 1 |
| Beckmann, RP; Beeram, M; Chan, EM; Cronier, DM; Flaherty, KT; Frenzel, M; Fulford, AD; Gandhi, L; Goldman, JW; Hilton, JF; Kulanthaivel, P; Li, LQ; Martinez, R; Nasir, A; Nguyen, TS; Papadopoulos, KP; Patnaik, A; Rasco, DW; Rosen, LS; Schade, AE; Shapiro, GI; Tolaney, SM; Tolcher, AW; Wen, PY | 1 |
| André, F; Auger, N; Besse, B; Facchinetti, F; Farace, F; Friboulet, L; Kuo, MS; Lacroix, L; Loriot, Y; Mahjoubi, L; Planchard, D; Remon, J; Scoazec, JY; Soria, JC | 1 |
| Benes, CH; Channick, C; Chin, E; Dagogo-Jack, I; Dardaei, L; Dias-Santagata, D; DiCecca, RH; Digumarthy, S; Engelman, JA; Friboulet, L; Gadgeel, S; Gainor, JF; Getz, G; Heist, RS; Huynh, T; Iafrate, AJ; Katayama, R; Keyes, C; Le, LP; Lee, D; Lennerz, J; Leshchiner, I; Lockerman, E; Logan, J; Mino-Kenudson, M; Muniappan, A; Parks, M; Ritterhouse, LL; Schultz, K; Sequist, LV; Shaw, AT; Singh, M; Yoda, S | 1 |
| Chen, M; Chen, T; Feng, J; Gao, L; Guo, H; Liang, Y; Liu, F; Liu, JJ; Ren, H; Shang, D; Shi, P; Thakur, A; Wang, T; Xu, F; Yang, T; Zhang, S | 1 |
| Bria, E; Brunelli, M; Caccese, M; Caliò, A; Carbognin, L; Cuppone, F; Ferrara, R; Grizzi, G; Petraglia, S; Pilotto, S; Scarpa, A; Tortora, G | 1 |
| Bankovic, J; Dragoj, M; Milosevic, Z; Pesic, M; Stankovic, T; Tanic, N | 1 |
| Ali, SM; Fernandez-Rocha, MY; Gitlitz, BJ; Lee, TK; Milliken, J; Ou, SI; Pavlick, D; Schrock, AB; Young, L; Zhu, VW | 1 |
| Chen, M; Khuri, FR; Owonikoko, TK; Ramalingam, SS; Ren, H; Sun, SY; Tao, H; Yue, P | 1 |
| Dicker, AP; Du, R; Li, B; Lu, B; Sun, Y; Torossian, A | 1 |
| Ishikawa, D; Kita, K; Matsumoto, K; Mitsudomi, T; Nakagawa, T; Nakamura, T; Nanjo, S; Sano, T; Sekido, Y; Suda, K; Takeuchi, S; Uenaka, T; Yamada, T; Yano, S | 1 |
20 review(s) available for alpha-aminopyridine and Carcinoma, Non-Small Cell Lung
| Article | Year |
|---|---|
Comparative efficacy and safety of first-line treatments for advanced non-small cell lung cancer with ALK-rearranged: a meta-analysis of clinical trials.
Topics: Aminopyridines; Anaplastic Lymphoma Kinase; Antineoplastic Agents; Carbazoles; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Gene Rearrangement; Humans; Lactams; Lung Neoplasms; Network Meta-Analysis; Organophosphorus Compounds; Piperazines; Piperidines; Progression-Free Survival; Protein Kinase Inhibitors; Pyrazoles; Pyridazines; Pyrimidines; Randomized Controlled Trials as Topic; Treatment Outcome | 2021 |
[Central nervous system disorders on lorlatinib: How to detect and manage in practice?]
Topics: Aminopyridines; Anaplastic Lymphoma Kinase; Carcinoma, Non-Small-Cell Lung; Central Nervous System Diseases; Drug-Related Side Effects and Adverse Reactions; Humans; Lactams; Lactams, Macrocyclic; Lung Neoplasms; Protein Kinase Inhibitors; Pyrazoles; Quality of Life | 2022 |
Lorlatinib as a treatment for ALK-positive lung cancer.
Topics: Aminopyridines; Anaplastic Lymphoma Kinase; Carcinoma, Non-Small-Cell Lung; Humans; Lactams; Lactams, Macrocyclic; Lung Neoplasms; Protein Kinase Inhibitors; Pyrazoles | 2022 |
An update on lorlatinib: a novel first line treatment for
Topics: Aminopyridines; Anaplastic Lymphoma Kinase; Carcinoma, Non-Small-Cell Lung; Humans; Lactams; Lactams, Macrocyclic; Lung Neoplasms; Protein Kinase Inhibitors; Protein-Tyrosine Kinases | 2023 |
Plain language summary of the updated results from the CROWN study comparing lorlatinib with crizotinib in people with advanced non-small-cell lung cancer.
Topics: Aminopyridines; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Crizotinib; Humans; Lactams, Macrocyclic; Lung Neoplasms; Protein Kinase Inhibitors | 2023 |
Lorlatinib for the treatment of
Topics: Aminopyridines; Anaplastic Lymphoma Kinase; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; Gene Rearrangement; Humans; Lactams; Lactams, Macrocyclic; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Pyrazoles | 2020 |
A user's guide to lorlatinib.
Topics: Aminopyridines; Carcinoma, Non-Small-Cell Lung; Humans; Lactams; Lactams, Macrocyclic; Lung Neoplasms; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Proteins; Pyrazoles | 2020 |
Pharmacological and clinical properties of lorlatinib in the treatment of
Topics: Aminopyridines; Anaplastic Lymphoma Kinase; Animals; Antineoplastic Agents; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Drug Evaluation, Preclinical; Humans; Lactams; Lactams, Macrocyclic; Lung Neoplasms; Pyrazoles; Treatment Outcome | 2020 |
Brigatinib and lorlatinib: their effect on ALK inhibitors in NSCLC focusing on resistant mutations and central nervous system metastases.
Topics: Aminopyridines; Anaplastic Lymphoma Kinase; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Central Nervous System Neoplasms; Crizotinib; Drug Resistance, Neoplasm; Humans; Lactams; Lactams, Macrocyclic; Lung Neoplasms; Mutation; Organophosphorus Compounds; Protein Kinase Inhibitors; Pyrazoles; Pyrimidines | 2021 |
A possible mechanism of hyperlipidemia in a patient with metastatic non-small cell lung cancer on lorlatinib therapy.
Topics: Aminopyridines; Carcinoma, Non-Small-Cell Lung; Female; Humans; Hyperlipidemias; Lactams; Lung Neoplasms; Middle Aged; Pyrazoles | 2021 |
Comparison of lorlatinib, alectinib and brigatinib in ALK inhibitor-naive/untreated ALK-positive advanced non-small-cell lung cancer: a systematic review and network meta-analysis.
Topics: Aminopyridines; Anaplastic Lymphoma Kinase; Carbazoles; Carcinoma, Non-Small-Cell Lung; Humans; Lactams; Lung Neoplasms; Network Meta-Analysis; Organophosphorus Compounds; Piperidines; Protein Kinase Inhibitors; Pyrazoles; Pyrimidines | 2022 |
Oncogene addiction in non-small cell lung cancer: Focus on ROS1 inhibition.
Topics: Aminopyridines; Anilides; Antineoplastic Agents; Benzamides; Carcinoma, Non-Small-Cell Lung; Crizotinib; Drug Resistance, Neoplasm; Gene Rearrangement; Humans; Indazoles; Lactams; Lactams, Macrocyclic; Lung Neoplasms; Molecular Diagnostic Techniques; Oncogene Fusion; Protein-Tyrosine Kinases; Proto-Oncogene Proteins; Pyrazoles; Pyridines; Pyrimidines; Sulfones | 2017 |
The accelerated path of ceritinib: Translating pre-clinical development into clinical efficacy.
Topics: Aminopyridines; Anaplastic Lymphoma Kinase; Antineoplastic Agents; Carbazoles; Carcinoma, Non-Small-Cell Lung; Humans; Lactams; Lactams, Macrocyclic; Lung Neoplasms; Organophosphorus Compounds; Piperidines; Pyrazoles; Pyrimidines; Receptor Protein-Tyrosine Kinases; Sulfones | 2017 |
First macrocyclic 3
Topics: Aminopyridines; Anaplastic Lymphoma Kinase; Animals; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Drug Evaluation, Preclinical; Humans; Lactams; Lactams, Macrocyclic; Lung; Lung Neoplasms; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Proteins; Pyrazoles; Receptor Protein-Tyrosine Kinases | 2017 |
Directed Therapies in Anaplastic Lymphoma Kinase-rearranged Non-small Cell Lung Cancer.
Topics: Aminopyridines; Anaplastic Lymphoma Kinase; Antineoplastic Agents; Carbazoles; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Crizotinib; Drug Resistance, Neoplasm; Humans; Lactams; Lactams, Macrocyclic; Lung Neoplasms; Mutation; Organophosphorus Compounds; Piperidines; Pyrazoles; Pyridines; Pyrimidines; Receptor Protein-Tyrosine Kinases; Small Molecule Libraries | 2018 |
Lorlatinib: First Global Approval.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Aminopyridines; Anaplastic Lymphoma Kinase; Carcinoma, Non-Small-Cell Lung; Child; Drug Approval; Humans; Japan; Lactams; Lactams, Macrocyclic; Middle Aged; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Proteins; Pyrazoles; United States; United States Food and Drug Administration | 2019 |
Lorlatinib for the treatment of anaplastic lymphoma kinase-positive non-small cell lung cancer.
Topics: Aminopyridines; Anaplastic Lymphoma Kinase; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; Humans; Lactams; Lactams, Macrocyclic; Lung Neoplasms; Protein Kinase Inhibitors; Pyrazoles | 2019 |
Insights into brain metastasis in patients with ALK+ lung cancer: is the brain truly a sanctuary?
Topics: Aminopyridines; Anaplastic Lymphoma Kinase; Antineoplastic Agents; Brain; Brain Neoplasms; Carbazoles; Carcinoma, Non-Small-Cell Lung; Crizotinib; Humans; Lactams; Lactams, Macrocyclic; Lung Neoplasms; Organophosphorus Compounds; Piperidines; Protein Kinase Inhibitors; Pyrazoles; Pyridines; Pyrimidines; Receptor Protein-Tyrosine Kinases; Sulfones | 2015 |
Second- and third-generation ALK inhibitors for non-small cell lung cancer.
Topics: Aminopyridines; Anaplastic Lymphoma Kinase; Carbazoles; Carcinoma, Non-Small-Cell Lung; Humans; Kaplan-Meier Estimate; Lactams; Lactams, Macrocyclic; Lung Neoplasms; Organophosphorus Compounds; Piperidines; Protein Kinase Inhibitors; Pyrazoles; Pyrimidines; Receptor Protein-Tyrosine Kinases; Sulfones | 2016 |
Current and developing therapies for the treatment of non-small cell lung cancer with ALK abnormalities: update and perspectives for clinical practice.
Topics: Aminopyridines; Anaplastic Lymphoma Kinase; Antineoplastic Agents; Carbazoles; Carcinoma, Non-Small-Cell Lung; Crizotinib; Drug Resistance, Neoplasm; Humans; Lactams; Lactams, Macrocyclic; Lung Neoplasms; Piperidines; Precision Medicine; Protein Kinase Inhibitors; Pyrazoles; Pyridines; Receptor Protein-Tyrosine Kinases | 2016 |
27 trial(s) available for alpha-aminopyridine and Carcinoma, Non-Small Cell Lung
| Article | Year |
|---|---|
A Phase I Study to Evaluate the Pharmacokinetics and Safety of Lorlatinib in Adults with Mild, Moderate, and Severe Renal Impairment.
Topics: Adult; Aminopyridines; Area Under Curve; Carcinoma, Non-Small-Cell Lung; Humans; Lactams; Lung Neoplasms; Pyrazoles; Renal Insufficiency | 2022 |
Continuation of Lorlatinib in ALK-Positive NSCLC Beyond Progressive Disease.
Topics: Aminopyridines; Carcinoma, Non-Small-Cell Lung; Humans; Lactams; Lactams, Macrocyclic; Lung Neoplasms; Protein Kinase Inhibitors; Pyrazoles; Receptor Protein-Tyrosine Kinases; Retrospective Studies | 2022 |
Phase Ib/II study of ceritinib in combination with ribociclib in patients with ALK-rearranged non-small cell lung cancer.
Topics: Adult; Aminopyridines; Anaplastic Lymphoma Kinase; Carcinoma, Non-Small-Cell Lung; Humans; Lung Neoplasms; Middle Aged; Protein Kinase Inhibitors; Purines; Pyrimidines; Receptor Protein-Tyrosine Kinases; Sulfones | 2022 |
Lorlatinib for Previously Treated ALK-Positive Advanced NSCLC: Primary Efficacy and Safety From a Phase 2 Study in People's Republic of China.
Topics: Aminopyridines; Carcinoma, Non-Small-Cell Lung; Cohort Studies; Crizotinib; Humans; Lactams; Lung Neoplasms; Protein Kinase Inhibitors; Pyrazoles; Receptor Protein-Tyrosine Kinases; Taiwan | 2022 |
Phase II Study of Lorlatinib in Patients With Anaplastic Lymphoma Kinase-Positive Lung Cancer and CNS-Specific Relapse.
Topics: Aminopyridines; Anaplastic Lymphoma Kinase; Carcinoma, Non-Small-Cell Lung; Humans; Lactams; Lactams, Macrocyclic; Lung Neoplasms; Neoplasm Recurrence, Local; Protein Kinase Inhibitors; Pyrazoles | 2022 |
Efficacy and safety of lorlatinib in Asian and non-Asian patients with ALK-positive advanced non-small cell lung cancer: Subgroup analysis of a global phase 2 trial.
Topics: Aminopyridines; Asian People; Carcinoma, Non-Small-Cell Lung; Humans; Lactams; Lung Neoplasms; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Proteins; Pyrazoles | 2022 |
A phase 1b study of necitumumab in combination with abemaciclib in patients with stage IV non-small cell lung cancer.
Topics: Adenocarcinoma of Lung; Adult; Aged; Aged, 80 and over; Aminopyridines; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Survival Rate; Tissue Distribution; Treatment Outcome | 2019 |
Lorlatinib in advanced ROS1-positive non-small-cell lung cancer: a multicentre, open-label, single-arm, phase 1-2 trial.
Topics: Adolescent; Adult; Aminopyridines; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Humans; Lactams; Lactams, Macrocyclic; Lung Neoplasms; Male; Middle Aged; Prognosis; Protein-Tyrosine Kinases; Proto-Oncogene Proteins; Pyrazoles; Response Evaluation Criteria in Solid Tumors; Survival Rate; Young Adult | 2019 |
The Effect of Rifampin on the Pharmacokinetics and Safety of Lorlatinib: Results of a Phase One, Open-Label, Crossover Study in Healthy Participants.
Topics: Adult; Aminopyridines; Antineoplastic Agents; Area Under Curve; Carcinoma, Non-Small-Cell Lung; Cross-Over Studies; Drug Interactions; Female; Healthy Volunteers; Humans; Lactams; Lactams, Macrocyclic; Lung Neoplasms; Male; Middle Aged; Pyrazoles; Rifampin; Young Adult | 2020 |
Brain Penetration of Lorlatinib: Cumulative Incidences of CNS and Non-CNS Progression with Lorlatinib in Patients with Previously Treated ALK-Positive Non-Small-Cell Lung Cancer.
Topics: Adult; Aged; Aged, 80 and over; Aminopyridines; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Disease Progression; Female; Humans; Incidence; Lactams; Lactams, Macrocyclic; Lung Neoplasms; Male; Middle Aged; Pyrazoles | 2020 |
First-Line Lorlatinib or Crizotinib in Advanced
Topics: Adult; Aged; Aminopyridines; Anaplastic Lymphoma Kinase; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Crizotinib; Female; Humans; Hyperlipidemias; Intention to Treat Analysis; Lactams; Lactams, Macrocyclic; Lung Neoplasms; Male; Middle Aged; Mutation; Pyrazoles; Survival Analysis | 2020 |
Population pharmacokinetic model with time-varying clearance for lorlatinib using pooled data from patients with non-small cell lung cancer and healthy participants.
Topics: Adult; Aminopyridines; Anaplastic Lymphoma Kinase; Carcinoma, Non-Small-Cell Lung; Female; Healthy Volunteers; Hepatic Insufficiency; Humans; Lactams; Lung Neoplasms; Male; Middle Aged; Prognosis; Protein-Tyrosine Kinases; Proto-Oncogene Proteins; Proton Pump Inhibitors; Pyrazoles; Renal Insufficiency; Serum Albumin | 2021 |
Intracranial and extracranial efficacy of lorlatinib in patients with ALK-positive non-small-cell lung cancer previously treated with second-generation ALK TKIs.
Topics: Aminopyridines; Carcinoma, Non-Small-Cell Lung; Humans; Lactams; Lactams, Macrocyclic; Lung Neoplasms; Protein Kinase Inhibitors; Pyrazoles; Receptor Protein-Tyrosine Kinases | 2021 |
The Effect of Modafinil on the Safety and Pharmacokinetics of Lorlatinib: A Phase I Study in Healthy Participants.
Topics: Aminopyridines; Area Under Curve; Carcinoma, Non-Small-Cell Lung; Drug Interactions; Healthy Volunteers; Humans; Lactams; Lung Neoplasms; Modafinil; Pyrazoles | 2021 |
Pharmacokinetics of Lorlatinib After Single and Multiple Dosing in Patients with Anaplastic Lymphoma Kinase (ALK)-Positive Non-Small Cell Lung Cancer: Results from a Global Phase I/II Study.
Topics: Aminopyridines; Anaplastic Lymphoma Kinase; Carcinoma, Non-Small-Cell Lung; Humans; Lactams; Lung Neoplasms; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Proteins; Pyrazoles | 2021 |
Lorlatinib Exposure-Response Analyses for Safety and Efficacy in a Phase I/II Trial to Support Benefit-Risk Assessment in Non-Small Cell Lung Cancer.
Topics: Adult; Aged; Aminopyridines; Carcinoma, Non-Small-Cell Lung; Dose-Response Relationship, Drug; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Hypercholesterolemia; Lactams; Lung Neoplasms; Male; Middle Aged; Pyrazoles; Risk Assessment; Treatment Outcome | 2021 |
The Cost-Effectiveness of Lorlatinib Versus Chemotherapy as a Second- or Third-Line Treatment in Anaplastic Lymphoma Kinase (ALK)-Positive Non-small-cell Lung Cancer in Sweden.
Topics: Aminopyridines; Anaplastic Lymphoma Kinase; Carcinoma, Non-Small-Cell Lung; Cost-Benefit Analysis; Humans; Lactams; Lung Neoplasms; Protein-Tyrosine Kinases; Proto-Oncogene Proteins; Pyrazoles; Quality-Adjusted Life Years; Sweden | 2021 |
Phase 1 Study Evaluating the Effects of the Proton Pump Inhibitor Rabeprazole and Food on the Pharmacokinetics of Lorlatinib in Healthy Participants.
Topics: Adult; Aminopyridines; Carcinoma, Non-Small-Cell Lung; Cross-Over Studies; Drug Interactions; Female; Food; Food-Drug Interactions; Healthy Volunteers; Humans; Lactams; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Proton Pump Inhibitors; Pyrazoles; Rabeprazole; Young Adult | 2021 |
Lorlatinib in non-small-cell lung cancer with ALK or ROS1 rearrangement: an international, multicentre, open-label, single-arm first-in-man phase 1 trial.
Topics: Adult; Aged; Aminopyridines; Anaplastic Lymphoma Kinase; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Gene Rearrangement; Humans; Internationality; Lactams; Lactams, Macrocyclic; Lung Neoplasms; Maximum Tolerated Dose; Middle Aged; Patient Selection; Prognosis; Prospective Studies; Protein-Tyrosine Kinases; Proto-Oncogene Mas; Proto-Oncogene Proteins; Pyrazoles; Receptor Protein-Tyrosine Kinases; Risk Assessment; Survival Analysis; Treatment Outcome | 2017 |
Lorlatinib in patients with ALK-positive non-small-cell lung cancer: results from a global phase 2 study.
Topics: Adult; Aged; Aged, 80 and over; Aminopyridines; Anaplastic Lymphoma Kinase; Antineoplastic Agents; Biomarkers, Tumor; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Female; Gene Rearrangement; Humans; Lactams; Lactams, Macrocyclic; Lung Neoplasms; Male; Middle Aged; Progression-Free Survival; Protein Kinase Inhibitors; Pyrazoles; Time Factors; Tumor Burden | 2018 |
Topics: Aminopyridines; Anaplastic Lymphoma Kinase; Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Clinical Decision-Making; Disease Progression; DNA Mutational Analysis; Drug Resistance, Neoplasm; Humans; Lactams; Lactams, Macrocyclic; Lung Neoplasms; Mutation; Patient Selection; Progression-Free Survival; Protein Kinase Inhibitors; Pyrazoles; Risk Factors; Time Factors | 2019 |
Buparlisib with thoracic radiotherapy and its effect on tumour hypoxia: A phase I study in patients with advanced non-small cell lung carcinoma.
Topics: Adenocarcinoma of Lung; Aged; Aminopyridines; Anorexia; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Chemoradiotherapy; Fatigue; Female; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Misonidazole; Morpholines; Nausea; Phosphoinositide-3 Kinase Inhibitors; Positron Emission Tomography Computed Tomography; Radiation-Sensitizing Agents; Radiotherapy; Tumor Hypoxia | 2019 |
A multi-histology trial of fostamatinib in patients with advanced colorectal, non-small cell lung, head and neck, thyroid, and renal cell carcinomas, and pheochromocytomas.
Topics: Adrenal Gland Neoplasms; Adult; Aged; Aged, 80 and over; Aminopyridines; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Cohort Studies; Colorectal Neoplasms; Endothelial Cells; Female; Head and Neck Neoplasms; Humans; Kidney Neoplasms; Lung Neoplasms; Male; Middle Aged; Morpholines; Neoplasms; Oxazines; Pheochromocytoma; Protein Kinase Inhibitors; Pyridines; Pyrimidines; Thyroid Neoplasms | 2013 |
Safety and Efficacy of Buparlisib (BKM120) in Patients with PI3K Pathway-Activated Non-Small Cell Lung Cancer: Results from the Phase II BASALT-1 Study.
Topics: Aged; Aminopyridines; Carcinoma, Non-Small-Cell Lung; Female; Humans; Lung Neoplasms; Male; Middle Aged; Morpholines; Neoplasm Metastasis; Phosphatidylinositol 3-Kinases | 2015 |
Treatment Rationale and Study Design for the JUNIPER Study: A Randomized Phase III Study of Abemaciclib With Best Supportive Care Versus Erlotinib With Best Supportive Care in Patients With Stage IV Non-Small-Cell Lung Cancer With a Detectable KRAS Mutati
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Cisplatin; Drug Resistance, Neoplasm; Erlotinib Hydrochloride; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Palliative Care; Prognosis; Proto-Oncogene Proteins p21(ras); Salvage Therapy; Survival Rate; Young Adult | 2016 |
Resensitization to Crizotinib by the Lorlatinib ALK Resistance Mutation L1198F.
Topics: Aminopyridines; Anaplastic Lymphoma Kinase; Binding Sites; Carcinoma, Non-Small-Cell Lung; Crizotinib; Drug Resistance, Neoplasm; Female; Humans; Lactams; Lactams, Macrocyclic; Liver Failure; Liver Neoplasms; Lung Neoplasms; Middle Aged; Molecular Structure; Mutation; Protein Kinase Inhibitors; Pyrazoles; Pyridines; Pyrimidines; Receptor Protein-Tyrosine Kinases; Sulfones | 2016 |
Crizotinib-Resistant ROS1 Mutations Reveal a Predictive Kinase Inhibitor Sensitivity Model for ROS1- and ALK-Rearranged Lung Cancers.
Topics: Aminopyridines; Anaplastic Lymphoma Kinase; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Crizotinib; Drug Resistance, Neoplasm; Humans; Lactams; Lactams, Macrocyclic; Lung Neoplasms; Male; Middle Aged; Mutation; Oncogene Proteins, Fusion; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Proteins; Pyrazoles; Pyridines; Pyrimidines; Receptor Protein-Tyrosine Kinases; Sulfones | 2016 |
98 other study(ies) available for alpha-aminopyridine and Carcinoma, Non-Small Cell Lung
| Article | Year |
|---|---|
Plain language summary of the CROWN study comparing lorlatinib with crizotinib for people with untreated non-small cell lung cancer.
Topics: Aminopyridines; Anaplastic Lymphoma Kinase; Carcinoma, Non-Small-Cell Lung; Crizotinib; Humans; Lactams; Language; Lung Neoplasms; Pyrazoles | 2021 |
Successful treatment with lorlatinib in a patient with meningeal carcinomatosis of ALK-positive non-small cell lung cancer resistant to alectinib and brigatinib: A case report.
Topics: Aminopyridines; Anaplastic Lymphoma Kinase; Carbazoles; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; Female; Humans; Lactams; Lung Neoplasms; Meningeal Carcinomatosis; Middle Aged; Organophosphorus Compounds; Piperidines; Protein-Tyrosine Kinases; Proto-Oncogene Proteins; Pyrazoles; Pyrimidines | 2021 |
The CLIP1-LTK fusion is an oncogenic driver in non-small-cell lung cancer.
Topics: Adenocarcinoma of Lung; Aminopyridines; Animals; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Transformation, Neoplastic; Chromosomes, Human, Pair 12; Chromosomes, Human, Pair 15; Humans; Lactams; Lung Neoplasms; Mice; Mice, Nude; Microtubule-Associated Proteins; Neoplasm Proteins; Oncogene Proteins, Fusion; Pyrazoles; Receptor Protein-Tyrosine Kinases; Xenograft Model Antitumor Assays | 2021 |
Podcast on the Management of Adverse Events Associated with Lorlatinib.
Topics: Aminopyridines; Carcinoma, Non-Small-Cell Lung; Humans; Lactams; Lactams, Macrocyclic; Lung Neoplasms; Pyrazoles | 2022 |
Lorlatinib for advanced ROS1+ non-small-cell lung cancer: results of the IFCT-1803 LORLATU study.
Topics: Aminopyridines; Carcinoma, Non-Small-Cell Lung; Female; Humans; Lactams; Lactams, Macrocyclic; Lung Neoplasms; Male; Middle Aged; Protein-Tyrosine Kinases; Proto-Oncogene Proteins; Pyrazoles | 2022 |
Lorlatinib for advanced anaplastic lymphoma kinase-positive non-small cell lung cancer: Results of the IFCT-1803 LORLATU cohort.
Topics: Aminopyridines; Anaplastic Lymphoma Kinase; Carcinoma, Non-Small-Cell Lung; Female; Humans; Lactams; Lactams, Macrocyclic; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Pyrazoles | 2022 |
Rapid and durable response to fifth-line lorlatinib plus olaparib in an ALK -rearranged, BRCA2-mutated metastatic lung adenocarcinoma patient with critical tracheal stenosis: a case report.
Topics: Adenocarcinoma of Lung; Adult; Aminopyridines; Anaplastic Lymphoma Kinase; BRCA2 Protein; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Female; Humans; Lactams; Lactams, Macrocyclic; Lung Neoplasms; Phthalazines; Piperazines; Poly(ADP-ribose) Polymerase Inhibitors; Protein Kinase Inhibitors; Pyrazoles; Receptor Protein-Tyrosine Kinases; Tracheal Stenosis | 2022 |
Evaluation of Lorlatinib Cerebrospinal Fluid Concentrations in Relation to Target Concentrations for Anaplastic Lymphoma Kinase (ALK) Inhibition.
Topics: Aminopyridines; Anaplastic Lymphoma Kinase; Carcinoma, Non-Small-Cell Lung; Humans; Lactams; Lactams, Macrocyclic; Lung Neoplasms; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Proteins; Pyrazoles | 2022 |
Successful treatment of refractory brain metastases from ALK-positive lung cancer with lorlatinib.
Topics: Adult; Aminopyridines; Anaplastic Lymphoma Kinase; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; Female; Humans; Lactams; Lung Neoplasms; Protein Kinase Inhibitors; Pyrazoles | 2022 |
Lorlatinib Exposed: A Far From Optimal Dose.
Topics: Aminopyridines; Carcinoma, Non-Small-Cell Lung; Humans; Lactams; Lactams, Macrocyclic; Lung Neoplasms; Protein Kinase Inhibitors; Pyrazoles | 2022 |
Lorlatinib in Frontline Therapy for ALK+ Advanced Non-Small-Cell Lung Cancer: Still a Matter of Debate?
Topics: Aminopyridines; Carcinoma, Non-Small-Cell Lung; Humans; Lactams, Macrocyclic; Lung Neoplasms; Protein Kinase Inhibitors; Pyrazoles; Receptor Protein-Tyrosine Kinases | 2022 |
[New drug approval: First-line lorlatinib in advanced ALK-positive non-small cell lung cancer].
Topics: Aminopyridines; Carcinoma, Non-Small-Cell Lung; Drug Approval; Humans; Lactams; Lactams, Macrocyclic; Lung Neoplasms; Protein Kinase Inhibitors; Pyrazoles; Receptor Protein-Tyrosine Kinases | 2022 |
Analysis of lorlatinib analogs reveals a roadmap for targeting diverse compound resistance mutations in ALK-positive lung cancer.
Topics: Aminopyridines; Anaplastic Lymphoma Kinase; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; Humans; Lactams; Lactams, Macrocyclic; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Pyrazoles | 2022 |
Therapy for Stage IV Non-Small-Cell Lung Cancer With Driver Alterations: ASCO Living Guideline.
Topics: Aminopyridines; Anaplastic Lymphoma Kinase; Carcinoma, Non-Small-Cell Lung; Crizotinib; Humans; Lactams; Lung Neoplasms; Organophosphorus Compounds; Protein Kinase Inhibitors; Pyrazoles; Pyrimidines | 2022 |
Establishment of an acquired lorlatinib-resistant cell line of non-small cell lung cancer and its mediated resistance mechanism.
Topics: Aminopyridines; Anaplastic Lymphoma Kinase; Carcinoma, Non-Small-Cell Lung; Cell Line; Cisplatin; Crizotinib; Docetaxel; Drug Resistance, Neoplasm; Humans; Lactams; Lactams, Macrocyclic; Lung Neoplasms; Microtubule Proteins; Mutation; Paclitaxel; Protein Kinase Inhibitors; Pyrazoles; Tumor Suppressor Protein p53 | 2022 |
Efficacy of lorlatinib after alectinib-induced interstitial lung disease in a patient with anaplastic lymphoma kinase-positive non-small cell lung cancer: a case report.
Topics: Aminopyridines; Anaplastic Lymphoma Kinase; Antineoplastic Agents; Carbazoles; Carcinoma, Non-Small-Cell Lung; Humans; Kidney Diseases; Lactams; Lung Diseases, Interstitial; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Piperidines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrazoles | 2022 |
[Chinese Expert Consensus on Management of Special Adverse Effects
Associated with Lorlatinib].
Topics: Aminopyridines; Carcinoma, Non-Small-Cell Lung; China; Consensus; Drug Resistance, Neoplasm; Drug-Related Side Effects and Adverse Reactions; Humans; Lactams; Lactams, Macrocyclic; Lung Neoplasms; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrazoles | 2022 |
Continuation of Lorlatinib May Bring Benefits to ALK-Positive NSCLC Beyond Progressive Disease; More Things Should Be Considered.
Topics: Aminopyridines; Carcinoma, Non-Small-Cell Lung; Humans; Lactams; Lung Neoplasms; Protein Kinase Inhibitors; Pyrazoles; Receptor Protein-Tyrosine Kinases | 2022 |
Silibinin Suppresses the Hyperlipidemic Effects of the ALK-Tyrosine Kinase Inhibitor Lorlatinib in Hepatic Cells.
Topics: Aminopyridines; Anaplastic Lymphoma Kinase; Carcinoma, Non-Small-Cell Lung; Cytochrome P-450 CYP3A; Hepatocytes; Humans; Lactams; Lactams, Macrocyclic; Lipids; Lung Neoplasms; Protein Kinase Inhibitors; Pyrazoles; Silybin; Tandem Mass Spectrometry; Triglycerides | 2022 |
Pan-HER inhibitors overcome lorlatinib resistance caused by NRG1/HER3 activation in ALK-rearranged lung cancer.
Topics: Aminopyridines; Anaplastic Lymphoma Kinase; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; Humans; Lactams, Macrocyclic; Lung Neoplasms; Mutation; Neuregulin-1; Protein Kinase Inhibitors | 2023 |
Acquired G2032R Resistance Mutation in ROS1 to Lorlatinib Therapy Detected with Liquid Biopsy.
Topics: Aminopyridines; Anaplastic Lymphoma Kinase; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; Humans; Lactams; Lactams, Macrocyclic; Liquid Biopsy; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Proteins; Pyrazoles; Tumor Suppressor Protein p53 | 2022 |
Factors Associated With Developing Neurocognitive Adverse Events in Patients Receiving Lorlatinib After Progression on Other Targeted Therapies.
Topics: Aminopyridines; Anaplastic Lymphoma Kinase; Anticonvulsants; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Humans; Lactams, Macrocyclic; Lung Neoplasms; Prospective Studies; Protein Kinase Inhibitors | 2023 |
Cost-effectiveness of ensartinib, crizotinib, ceritinib, alectinib, brigatinib and lorlatinib in patients with anaplastic lymphoma kinase-positive non-small cell lung cancer in China.
Topics: Aminopyridines; Anaplastic Lymphoma Kinase; Carbazoles; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Cost-Benefit Analysis; Crizotinib; Humans; Lactams; Lung Neoplasms; Network Meta-Analysis; Organophosphorus Compounds; Piperazines; Piperidines; Protein Kinase Inhibitors; Pyrazoles; Pyridazines; Pyrimidines; Sulfones | 2022 |
NVL-520 Is a Selective, TRK-Sparing, and Brain-Penetrant Inhibitor of ROS1 Fusions and Secondary Resistance Mutations.
Topics: Aminopyridines; Brain; Carcinoma, Non-Small-Cell Lung; Humans; Lactams; Lactams, Macrocyclic; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Proteins; Pyrazoles | 2023 |
First-line lorlatinib for advanced ALK-positive non-small-cell lung cancer.
Topics: Aminopyridines; Carcinoma, Non-Small-Cell Lung; Humans; Lactams; Lactams, Macrocyclic; Lung Neoplasms; Protein Kinase Inhibitors; Receptor Protein-Tyrosine Kinases | 2023 |
Neurocognitive Adverse Events in Patients With ALK or ROS1-Positive, Advanced or Metastatic NSCLC Receiving Lorlatinib.
Topics: Aminopyridines; Carcinoma, Non-Small-Cell Lung; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Proteins; Receptor Protein-Tyrosine Kinases | 2023 |
The
Topics: Aminopyridines; Anaplastic Lymphoma Kinase; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Humans; Lactams, Macrocyclic; Lung Neoplasms; Protein Kinase Inhibitors; Receptor Protein-Tyrosine Kinases | 2023 |
Circulating tumor DNA reveals mechanisms of lorlatinib resistance in patients with relapsed/refractory ALK-driven neuroblastoma.
Topics: Aminopyridines; Anaplastic Lymphoma Kinase; Carcinoma, Non-Small-Cell Lung; Circulating Tumor DNA; Drug Resistance, Neoplasm; Humans; Lactams, Macrocyclic; Lung Neoplasms; Mutation; Neuroblastoma; Protein Kinase Inhibitors | 2023 |
The new-generation selective ROS1/NTRK inhibitor DS-6051b overcomes crizotinib resistant ROS1-G2032R mutation in preclinical models.
Topics: Aminopyridines; Benzamides; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Survival; Crizotinib; Drug Development; Drug Resistance, Neoplasm; Humans; Indazoles; Lactams; Lactams, Macrocyclic; Lung Neoplasms; Membrane Glycoproteins; Mutation; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Proteins; Pyrazoles; Receptor, trkB | 2019 |
Untapped potential: recognising CNS opportunities in early oncology drug development.
Topics: Aminopyridines; Carcinoma, Non-Small-Cell Lung; Drug Development; Humans; Lactams; Lactams, Macrocyclic; Lung Neoplasms; Protein-Tyrosine Kinases; Proto-Oncogene Proteins; Pyrazoles | 2019 |
A Compound L1196M/G1202R ALK Mutation in a Patient with ALK-Positive Lung Cancer with Acquired Resistance to Brigatinib Also Confers Primary Resistance to Lorlatinib.
Topics: Aged; Aminopyridines; Anaplastic Lymphoma Kinase; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; Humans; Lactams; Lactams, Macrocyclic; Lung Neoplasms; Mutation; Organophosphorus Compounds; Prognosis; Protein Kinase Inhibitors; Pyrazoles; Pyrimidines | 2019 |
Lorlatinib: a new treatment option for ROS1-positive lung cancer.
Topics: Aminopyridines; Carcinoma, Non-Small-Cell Lung; Humans; Lactams; Lactams, Macrocyclic; Lung Neoplasms; Protein-Tyrosine Kinases; Proto-Oncogene Proteins; Pyrazoles | 2019 |
Lorlatinib in ROS1-positive NSCLC.
Topics: Aminopyridines; Carcinoma, Non-Small-Cell Lung; Humans; Lactams; Lactams, Macrocyclic; Lung Neoplasms; Protein-Tyrosine Kinases; Proto-Oncogene Proteins; Pyrazoles | 2020 |
Drug resistance mechanisms in Japanese anaplastic lymphoma kinase-positive non-small cell lung cancer and the clinical responses based on the resistant mechanisms.
Topics: Aminopyridines; Anaplastic Lymphoma Kinase; Asian People; Carbazoles; Carcinoma, Non-Small-Cell Lung; Crizotinib; Drug Resistance, Neoplasm; Humans; Lactams; Lactams, Macrocyclic; Lung Neoplasms; Mutation; Piperidines; Protein Kinase Inhibitors; Pyrazoles; Pyrimidines; Recombinant Proteins; Sulfones | 2020 |
18F-FDG PET/CT Evaluation of Crizotinib and Lorlatinib Therapy in Metastatic ROS-1-Positive Non-Small Cell Lung Cancer.
Topics: Aminopyridines; Carcinoma, Non-Small-Cell Lung; Crizotinib; Fluorodeoxyglucose F18; Humans; Lactams; Lactams, Macrocyclic; Lung Neoplasms; Male; Middle Aged; Positron Emission Tomography Computed Tomography; Pyrazoles; Radiopharmaceuticals | 2020 |
Recent advances in targeted small-molecule inhibitor therapy for non-small-cell lung cancer-An update.
Topics: Aminopyridines; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Humans; Lactams; Lactams, Macrocyclic; Lung Neoplasms; Molecular Targeted Therapy; Organophosphorus Compounds; Pyrazoles; Pyrimidines | 2020 |
A novel ROS1 G2032 K missense mutation mediates lorlatinib resistance in a patient with ROS1-rearranged lung adenocarcinoma but responds to nab-paclitaxel plus pembrolizumab.
Topics: Adenocarcinoma of Lung; Albumins; Aminopyridines; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; Gene Rearrangement; Humans; Lactams; Lactams, Macrocyclic; Lung Neoplasms; Male; Middle Aged; Mutation, Missense; Paclitaxel; Prognosis; Protein-Tyrosine Kinases; Proto-Oncogene Proteins; Pyrazoles | 2020 |
Impact of lorlatinib on patient-reported outcomes in patients with advanced ALK-positive or ROS1-positive non-small cell lung cancer.
Topics: Aminopyridines; Carcinoma, Non-Small-Cell Lung; Humans; Lactams; Lactams, Macrocyclic; Lung Neoplasms; Patient Reported Outcome Measures; Protein-Tyrosine Kinases; Proto-Oncogene Proteins; Pyrazoles; Quality of Life; Surveys and Questionnaires | 2020 |
A case of one lung adenocarcinoma patient harboring a novel FAM179A-ALK (F1, A19) rearrangement responding to lorlatinib treatment.
Topics: Adenocarcinoma of Lung; Aminopyridines; Anaplastic Lymphoma Kinase; Carcinoma, Non-Small-Cell Lung; Gene Rearrangement; Humans; Lactams; Lactams, Macrocyclic; Lung Neoplasms; Protein Kinase Inhibitors; Pyrazoles | 2020 |
Lorlatinib in previously treated anaplastic lymphoma kinase-rearranged non-small cell lung cancer: Japanese subgroup analysis of a global study.
Topics: Aged; Aged, 80 and over; Aminopyridines; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; Drug-Related Side Effects and Adverse Reactions; Humans; Hypercholesterolemia; Lactams; Lactams, Macrocyclic; Middle Aged; Mutation; Neoplasm Metastasis; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Mas; Proto-Oncogene Proteins; Pyrazoles | 2020 |
Chidamide combined with paclitaxel effectively reverses the expression of histone deacetylase in lung cancer.
Topics: Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzamides; Carcinoma, Non-Small-Cell Lung; Cell Cycle; Histone Deacetylase 6; Histone Deacetylase Inhibitors; Histone Deacetylases; Humans; Lung Neoplasms; Paclitaxel; Proto-Oncogene Proteins c-myc; Tumor Cells, Cultured | 2020 |
Lorlatinib induced proteinuria: A case report.
Topics: Aged; Aminopyridines; Carcinoma, Non-Small-Cell Lung; Female; Humans; Lactams; Lactams, Macrocyclic; Lung Neoplasms; Protein Kinase Inhibitors; Proteinuria; Pyrazoles | 2021 |
Alectinib and lorlatinib function by modulating EMT-related proteins and MMPs in NSCLC metastasis.
Topics: Aminopyridines; Biomarkers, Tumor; Brain Neoplasms; Carbazoles; Carcinoma, Non-Small-Cell Lung; Cell Movement; Cell Survival; Down-Regulation; Epithelial-Mesenchymal Transition; Humans; Lactams; Lung Neoplasms; Matrix Metalloproteinases; Piperidines; Pyrazoles; Tumor Cells, Cultured | 2021 |
New lung-cancer drugs extend survival times.
Topics: Acrylamides; Afatinib; Aminopyridines; Anaplastic Lymphoma Kinase; Aniline Compounds; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; B7-H1 Antigen; Carbazoles; Carcinoma, Non-Small-Cell Lung; Crizotinib; ErbB Receptors; Gefitinib; Hope; Humans; Lactams; Lung; Lung Neoplasms; Piperidines; Programmed Cell Death 1 Receptor; Pyrazoles; Quinazolinones; Survival Analysis | 2020 |
Lorlatinib Outperforms Crizotinib in NSCLC.
Topics: Aminopyridines; Anaplastic Lymphoma Kinase; Carcinoma, Non-Small-Cell Lung; Crizotinib; Humans; Lactams; Lactams, Macrocyclic; Lung Neoplasms; Pyrazoles | 2021 |
Transformation from adenocarcinoma to squamous cell lung carcinoma with MET amplification after lorlatinib resistance: A case report.
Topics: Adenocarcinoma; Aminopyridines; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; Female; Humans; Lactams; Middle Aged; Pyrazoles | 2021 |
Lorlatinib in the treatment of anaplastic lymphoma kinase-positive non-small-cell lung cancer.
Topics: Aminopyridines; Anaplastic Lymphoma Kinase; Carcinoma, Non-Small-Cell Lung; Humans; Lactams; Lactams, Macrocyclic; Lung Neoplasms; Protein Kinase Inhibitors; Pyrazoles | 2021 |
Lorlatinib Should Not be Considered as the Preferred First-Line Option in Patients With Advanced ALK Rearranged NSCLC.
Topics: Aminopyridines; Carcinoma, Non-Small-Cell Lung; Humans; Lactams; Lactams, Macrocyclic; Lung Neoplasms; Protein Kinase Inhibitors; Pyrazoles; Receptor Protein-Tyrosine Kinases | 2021 |
Lorlatinib Should Be Considered as the Preferred First-Line Option in Patients With Advanced ALK-Rearranged NSCLC.
Topics: Aminopyridines; Carcinoma, Non-Small-Cell Lung; Humans; Lactams; Lactams, Macrocyclic; Lung Neoplasms; Protein Kinase Inhibitors; Pyrazoles; Receptor Protein-Tyrosine Kinases | 2021 |
Identification of a novel resistance ALK p.(Q1188_L1190del) deletion in a patient with ALK-rearranged non-small-cell lung cancer.
Topics: Adult; Aminopyridines; Anaplastic Lymphoma Kinase; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; Female; Gene Deletion; Humans; Lactams; Lung Neoplasms; Positron Emission Tomography Computed Tomography; Pyrazoles | 2021 |
Liver Toxicity Observed With Lorlatinib When Combined With Strong CYP3A Inducers: Evaluation of Cynomolgus Monkey as a Nonclinical Model for Assessing the Mechanism of Combinational Toxicity.
Topics: Aminopyridines; Animals; Carcinoma, Non-Small-Cell Lung; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inducers; Drug Interactions; Humans; Lactams; Lactams, Macrocyclic; Liver; Lung Neoplasms; Macaca fascicularis; Pyrazoles | 2021 |
[A Case of Non-small Cell Lung Cancer Treated with Three ALK Inhibitors
and Chemotherapy].
Topics: Aminopyridines; Anaplastic Lymphoma Kinase; Carcinoma, Non-Small-Cell Lung; Cell Cycle Proteins; Crizotinib; Female; Humans; Lactams; Lung Neoplasms; Microtubule-Associated Proteins; Middle Aged; Protein Kinase Inhibitors; Pyrazoles; Pyrimidines; Serine Endopeptidases; Sulfones | 2021 |
Monitoring and Managing Lorlatinib Adverse Events in the Portuguese Clinical Setting: A Position Paper.
Topics: Aminopyridines; Carcinoma, Non-Small-Cell Lung; Humans; Lactams; Lactams, Macrocyclic; Lung Neoplasms; Portugal; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Proteins; Pyrazoles | 2021 |
[Lorlatinib: a promising drug in the future treatment of advanced ALK-positive non-small-cell lung cancer].
Topics: Aminopyridines; Carcinoma, Non-Small-Cell Lung; Humans; Lactams; Lactams, Macrocyclic; Lung Neoplasms; Pharmaceutical Preparations; Protein Kinase Inhibitors; Pyrazoles; Receptor Protein-Tyrosine Kinases | 2021 |
Response to lorlatinib on a patient with ALK-rearranged non-small cell lung cancer harboring 1151Tins mutation with uterine metastasis.
Topics: Aminopyridines; Anaplastic Lymphoma Kinase; Antineoplastic Agents; Carbazoles; Carcinoma, Non-Small-Cell Lung; Crizotinib; Female; Gene Rearrangement; Humans; Lactams; Lung Neoplasms; Middle Aged; Mutation; Piperidines; Protein Kinase Inhibitors; Pyrazoles; Uterine Neoplasms | 2021 |
Dual targeting of MEK and PI3K effectively controls the proliferation of human EGFR-TKI resistant non-small cell lung carcinoma cell lines with different genetic backgrounds.
Topics: Afatinib; Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; ErbB Receptors; Humans; Lung Neoplasms; Mitogen-Activated Protein Kinase Kinases; Morpholines; Mutation; Phosphatidylinositol 3-Kinases; Protein Kinase Inhibitors; Pyrrolidinones; Quinolines | 2021 |
Real-world efficacy and safety of lorlatinib in treating advanced ALK-positive non-small cell lung cancer patients.
Topics: Adult; Aged; Aminopyridines; Anaplastic Lymphoma Kinase; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Female; Humans; Lactams; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Progression-Free Survival; Pyrazoles; Retrospective Studies | 2021 |
Lorlatinib Induces Durable Disease Stabilization in a Pancreatic Cancer Patient with a ROS1 p.L1950F Mutation: Case Report.
Topics: Aminopyridines; Carcinoma, Non-Small-Cell Lung; Humans; Lactams; Lung Neoplasms; Mutation; Pancreatic Neoplasms; Precision Medicine; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Mas; Proto-Oncogene Proteins; Pyrazoles | 2021 |
Resistance profiles of anaplastic lymphoma kinase tyrosine kinase inhibitors in advanced non-small-cell lung cancer: a multicenter study using targeted next-generation sequencing.
Topics: Adult; Aged; Aged, 80 and over; Aminopyridines; Anaplastic Lymphoma Kinase; Antineoplastic Agents; Carbazoles; Carcinoma, Non-Small-Cell Lung; Circulating Tumor DNA; Crizotinib; DNA Mutational Analysis; Drug Resistance, Neoplasm; Female; High-Throughput Nucleotide Sequencing; Humans; Lactams; Lung Neoplasms; Male; Middle Aged; Molecular Targeted Therapy; Mutation; Piperidines; Predictive Value of Tests; Prospective Studies; Protein Kinase Inhibitors; Pyrazoles; Pyrimidines; Risk Factors; Sulfones; Taiwan; Treatment Outcome | 2021 |
Taxane-Platin-Resistant Lung Cancers Co-develop Hypersensitivity to JumonjiC Demethylase Inhibitors.
Topics: Aminopyridines; Animals; Antineoplastic Agents; Benzazepines; Bridged-Ring Compounds; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Disease-Free Survival; Drug Resistance, Neoplasm; Enzyme Inhibitors; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Histones; Humans; Hydrazones; Jumonji Domain-Containing Histone Demethylases; Lung Neoplasms; Methylation; Mice; Neoadjuvant Therapy; Pyrimidines; Taxoids; Transcription, Genetic | 2017 |
Design, Synthesis, and Pharmacological Evaluation of Novel Multisubstituted Pyridin-3-amine Derivatives as Multitargeted Protein Kinase Inhibitors for the Treatment of Non-Small Cell Lung Cancer.
Topics: Aminopyridines; Animals; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Databases, Chemical; Drug Design; Drug Screening Assays, Antitumor; Female; Heterografts; Humans; Indazoles; Lung Neoplasms; Mice; Mice, Nude; Molecular Docking Simulation; Neoplasm Transplantation; Phosphorylation; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyridines; Rats, Sprague-Dawley; Signal Transduction; Stereoisomerism; Structure-Activity Relationship | 2017 |
KRIBB11 accelerates Mcl-1 degradation through an HSF1-independent, Mule-dependent pathway in A549 non-small cell lung cancer cells.
Topics: Aminopyridines; Apoptosis; Carcinoma, Non-Small-Cell Lung; DNA-Binding Proteins; Heat Shock Transcription Factors; HSP70 Heat-Shock Proteins; Humans; Indazoles; Lung Neoplasms; Myeloid Cell Leukemia Sequence 1 Protein; Proteasome Endopeptidase Complex; Proteolysis; Transcription Factors; Tumor Cells, Cultured; Tumor Suppressor Proteins; Ubiquitin-Protein Ligases | 2017 |
Investigation on the binding mechanism of loratinib with the c-ros oncogene 1 (ROS1) receptor tyrosine kinase via molecular dynamics simulation and binding free energy calculations.
Topics: Aminopyridines; Anaplastic Lymphoma Kinase; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Crizotinib; Drug Resistance, Neoplasm; Energy Metabolism; Humans; Lactams; Lactams, Macrocyclic; Molecular Dynamics Simulation; Mutation; Protein Binding; Protein-Tyrosine Kinases; Proto-Oncogene Proteins; Pyrazoles | 2018 |
Activation of Src signaling mediates acquired resistance to ALK inhibition in lung cancer.
Topics: Aminopyridines; Anaplastic Lymphoma Kinase; Animals; Antineoplastic Combined Chemotherapy Protocols; Carbazoles; Carcinoma, Non-Small-Cell Lung; Crizotinib; Drug Resistance, Neoplasm; Humans; Lactams; Lactams, Macrocyclic; Mice; Piperidines; Pyrazoles; Pyridines; Pyrimidines; Receptor Protein-Tyrosine Kinases; Signal Transduction; src-Family Kinases; Sulfones; Xenograft Model Antitumor Assays | 2017 |
Lorlatinib - Induced pulmonary arterial hypertension.
Topics: Aminopyridines; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Drug-Related Side Effects and Adverse Reactions; Dyspnea; Female; Humans; Hypertension, Pulmonary; Lactams; Lactams, Macrocyclic; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Pyrazoles; Vascular Resistance; Walk Test; Withholding Treatment | 2018 |
Inhibition of CXCR4 regulates epithelial mesenchymal transition of NSCLC via the Hippo-YAP signaling pathway.
Topics: A549 Cells; Aminopyridines; Benzylamines; Cadherins; Carcinoma, Non-Small-Cell Lung; Cell Cycle Proteins; Cell Line, Tumor; Cell Movement; Dose-Response Relationship, Drug; Epithelial-Mesenchymal Transition; Hippo Signaling Pathway; Humans; Lung Neoplasms; Neoplasm Invasiveness; Nuclear Proteins; Protein Serine-Threonine Kinases; Receptors, CXCR4; Signal Transduction; Snail Family Transcription Factors; Transcription Factors; Twist-Related Protein 1; Vimentin | 2018 |
New onset myasthenia gravis in a patient with non small cell lung cancer treated with lorlatinib a novel anti-cancer agent.
Topics: Aminopyridines; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Humans; Lactams; Lactams, Macrocyclic; Lung Neoplasms; Male; Middle Aged; Myasthenia Gravis; Pyrazoles | 2018 |
Sarcoid-like reaction mimicking disease progression in an ALK-positive lung cancer patient receiving lorlatinib.
Topics: Adult; Aminopyridines; Anaplastic Lymphoma Kinase; Carcinoma, Non-Small-Cell Lung; Diagnosis, Differential; Disease Progression; Female; Gene Rearrangement; Humans; Lactams; Lactams, Macrocyclic; Lung Neoplasms; Prognosis; Pyrazoles; Sarcoidosis | 2019 |
Lorlatinib: a new-generation drug for ALK-positive NSCLC.
Topics: Aminopyridines; Carcinoma, Non-Small-Cell Lung; Humans; Lactams; Lactams, Macrocyclic; Lung Neoplasms; Pyrazoles; Receptor Protein-Tyrosine Kinases | 2018 |
Lorlatinib Salvages CNS Relapse in an ALK-Positive Non-Small-Cell Lung Cancer Patient Previously Treated With Crizotinib and High-Dose Brigatinib.
Topics: Adult; Aminopyridines; Anaplastic Lymphoma Kinase; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Central Nervous System; Crizotinib; Drug Approval; Humans; Lactams; Lactams, Macrocyclic; Lung Neoplasms; Male; Neoplasm Metastasis; Organophosphorus Compounds; Pyrazoles; Pyrimidines; Recurrence; Treatment Outcome | 2019 |
Prediction of ALK mutations mediating ALK-TKIs resistance and drug re-purposing to overcome the resistance.
Topics: Aminopyridines; Anaplastic Lymphoma Kinase; Animals; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Drug Resistance, Neoplasm; HEK293 Cells; Humans; Lactams; Lactams, Macrocyclic; Lung Neoplasms; Mice; Mice, Inbred BALB C; Mice, Nude; Molecular Dynamics Simulation; Mutation, Missense; Protein Binding; Protein Kinase Inhibitors; Pyrazoles; Pyrimidines; Software; Sulfones | 2019 |
Chidamide-induced ROS accumulation and miR-129-3p-dependent cell cycle arrest in non-small lung cancer cells.
Topics: A549 Cells; Aminopyridines; Antineoplastic Agents; Benzamides; Carcinoma, Non-Small-Cell Lung; Cell Cycle Checkpoints; Cell Line, Tumor; Gene Expression Regulation, Neoplastic; Histone Deacetylase Inhibitors; Humans; Lung Neoplasms; MicroRNAs; Reactive Oxygen Species; Telomerase | 2019 |
Efficacy and Safety of Lorlatinib in Korean Non-Small-Cell Lung Cancer Patients With ALK or ROS1 Rearrangement Whose Disease Failed to Respond to a Previous Tyrosine Kinase Inhibitor.
Topics: Adult; Aged; Aminopyridines; Anaplastic Lymphoma Kinase; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; Female; Gene Rearrangement; Humans; Lactams; Lactams, Macrocyclic; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Proteins; Pyrazoles; Republic of Korea; Retrospective Studies | 2019 |
miR-100-5p confers resistance to ALK tyrosine kinase inhibitors Crizotinib and Lorlatinib in EML4-ALK positive NSCLC.
Topics: Aminopyridines; Anaplastic Lymphoma Kinase; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Cycle Proteins; Cell Line, Tumor; Crizotinib; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Humans; Lactams; Lactams, Macrocyclic; Lung Neoplasms; MicroRNAs; Microtubule-Associated Proteins; Oncogene Proteins, Fusion; Protein Kinase Inhibitors; Pyrazoles; Serine Endopeptidases | 2019 |
Lorlatinib for the treatment of patients with non-small cell lung cancer.
Topics: Aminopyridines; Anaplastic Lymphoma Kinase; Carcinoma, Non-Small-Cell Lung; Humans; Lactams; Lactams, Macrocyclic; Lung Neoplasms; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Proteins; Pyrazoles | 2019 |
Clinical Management of Adverse Events Associated with Lorlatinib.
Topics: Aged; Aminopyridines; Anaplastic Lymphoma Kinase; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase I as Topic; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Drug-Related Side Effects and Adverse Reactions; Humans; Lactams; Lactams, Macrocyclic; Lung Neoplasms; Middle Aged; Mutation; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Proteins; Pyrazoles; Severity of Illness Index; Treatment Outcome | 2019 |
The PI3K inhibitor buparlisib suppresses osteoclast formation and tumour cell growth in bone metastasis of lung cancer, as evidenced by multimodality molecular imaging.
Topics: Aminopyridines; Animals; Antineoplastic Agents; Apoptosis; Bone and Bones; Bone Neoplasms; Carcinoma, Non-Small-Cell Lung; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Male; Mice; Mice, Nude; Molecular Imaging; Morpholines; Osteoclasts; Positron Emission Tomography Computed Tomography; Single Photon Emission Computed Tomography Computed Tomography; Treatment Outcome; X-Ray Microtomography | 2019 |
Case Report: Temporal Heterogeneity of ALK Activating Mutations in Sequential ALK TKI-Treated Non-Small-Cell Lung Cancer Revealed Using NGS-Based Liquid Biopsy.
Topics: Aged; Aminopyridines; Anaplastic Lymphoma Kinase; Antineoplastic Agents; Carcinogenesis; Carcinoma, Non-Small-Cell Lung; Circulating Tumor DNA; Crizotinib; Drug Resistance, Neoplasm; Humans; Lactams; Lactams, Macrocyclic; Liquid Biopsy; Lung Neoplasms; Male; Mutation; Neoplasm Staging; Oncogene Proteins, Fusion; Organophosphorus Compounds; Protein Kinase Inhibitors; Pyrazoles; Pyrimidines | 2019 |
Complete response of spinal metastases from non-small cell lung cancer with ALK inhibitors.
Topics: Aminopyridines; Anaplastic Lymphoma Kinase; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Crizotinib; Female; Humans; Lactams; Lactams, Macrocyclic; Lung Neoplasms; Meningeal Neoplasms; Middle Aged; Protein Kinase Inhibitors; Pyrazoles; Pyrimidines; Spinal Cord Neoplasms; Sulfones; Treatment Outcome | 2019 |
Response to Crizotinib Re-administration After Progression on Lorlatinib in a Patient With ALK-rearranged Non-small-cell Lung Cancer.
Topics: Adult; Aminopyridines; Anaplastic Lymphoma Kinase; Carcinoma, Non-Small-Cell Lung; Crizotinib; Drug Resistance, Neoplasm; Female; Gene Rearrangement; Humans; Lactams; Lactams, Macrocyclic; Lung Neoplasms; Protein Kinase Inhibitors; Pyrazoles; Treatment Outcome | 2019 |
Rapid regression of neurological symptoms in patients with metastasised ALK+ lung cancer who are treated with lorlatinib: a report of two cases.
Topics: Aminopyridines; Anaplastic Lymphoma Kinase; Antineoplastic Agents; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Crizotinib; Female; Humans; Lactams; Lactams, Macrocyclic; Lung Neoplasms; Magnetic Resonance Imaging; Male; Middle Aged; Nervous System Diseases; Progression-Free Survival; Pyrazoles; Remission Induction; Treatment Outcome | 2019 |
The PI3 kinase inhibitor NVP-BKM120 induces GSK3/FBXW7-dependent Mcl-1 degradation, contributing to induction of apoptosis and enhancement of TRAIL-induced apoptosis.
Topics: Aminopyridines; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Cycle Proteins; Cell Line, Tumor; Down-Regulation; Drug Synergism; F-Box Proteins; F-Box-WD Repeat-Containing Protein 7; Glycogen Synthase Kinase 3; HCT116 Cells; Humans; Lung Neoplasms; Morpholines; Myeloid Cell Leukemia Sequence 1 Protein; Phosphatidylinositol 3-Kinase; Phosphoinositide-3 Kinase Inhibitors; Protein Kinase Inhibitors; Recombinant Proteins; TNF-Related Apoptosis-Inducing Ligand; Ubiquitin-Protein Ligases | 2013 |
The current state of molecularly targeted drugs targeting HGF/Met.
Topics: Acrylamides; Afatinib; Aminopyridines; Antibodies, Monoclonal; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Crizotinib; Drug Resistance, Neoplasm; Drugs, Investigational; ErbB Receptors; Gene Expression Regulation, Neoplastic; Hepatocyte Growth Factor; Humans; Lung Neoplasms; Molecular Targeted Therapy; Mutation; Neoplasms; Piperazines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-met; Pyrazoles; Pyridines; Pyrimidines; Pyrrolidinones; Quinazolines; Quinolines; Signal Transduction; Up-Regulation; Vascular Endothelial Growth Factor Receptor-2 | 2014 |
[Development and biochemical characterization of EGFR/c-Met dual inhibitors].
Topics: Afatinib; Aminopyridines; Anilides; Antineoplastic Agents; Apoptosis; Blotting, Western; Carcinoma, Non-Small-Cell Lung; Cell Line; Cell Line, Tumor; Computer Simulation; Crizotinib; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Imidazoles; Lapatinib; Lung Neoplasms; Molecular Structure; Protein Kinase Inhibitors; Protein Kinases; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-met; Pyrazines; Pyrazoles; Pyridines; Pyridones; Quinazolines; Quinolines | 2013 |
Non-toxic dose chidamide synergistically enhances platinum-induced DNA damage responses and apoptosis in Non-Small-Cell lung cancer cells.
Topics: Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzamides; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cisplatin; DNA Damage; Dose-Response Relationship, Drug; Drug Synergism; Flow Cytometry; Humans; Lung Neoplasms; Organoplatinum Compounds; Oxaliplatin | 2014 |
E2F inhibition synergizes with paclitaxel in lung cancer cell lines.
Topics: Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cisplatin; Deoxycytidine; Drug Synergism; E2F3 Transcription Factor; Gemcitabine; Humans; Hydroxyquinolines; Inhibitory Concentration 50; Lung Neoplasms; Paclitaxel; RNA, Small Interfering; Small Cell Lung Carcinoma | 2014 |
Mechanistic understanding of translational pharmacokinetic-pharmacodynamic relationships in nonclinical tumor models: a case study of orally available novel inhibitors of anaplastic lymphoma kinase.
Topics: Aminopyridines; Anaplastic Lymphoma Kinase; Animals; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Crizotinib; Female; Lactams; Lactams, Macrocyclic; Lung Neoplasms; Mice; Mice, Nude; Microtubule-Associated Proteins; Models, Biological; Protein Kinase Inhibitors; Pyrazoles; Pyridines; Receptor Protein-Tyrosine Kinases; Xenograft Model Antitumor Assays | 2015 |
Discovery of selective and noncovalent diaminopyrimidine-based inhibitors of epidermal growth factor receptor containing the T790M resistance mutation.
Topics: Amino Acid Substitution; Aminopyridines; Carcinoma, Non-Small-Cell Lung; Crystallography, X-Ray; Drug Resistance, Neoplasm; ErbB Receptors; High-Throughput Screening Assays; Humans; Lung Neoplasms; Methionine; Mutation; Protein Kinase Inhibitors; Threonine | 2014 |
PKD1 is downregulated in non-small cell lung cancer and mediates the feedback inhibition of mTORC1-S6K1 axis in response to phorbol ester.
Topics: Aminopyridines; Benzamides; Blotting, Western; Butadienes; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Chromones; Diphenylamine; Enzyme Activation; Humans; Mechanistic Target of Rapamycin Complex 1; Morpholines; Multiprotein Complexes; Nitriles; Phorbol Esters; Real-Time Polymerase Chain Reaction; Ribosomal Protein S6 Kinases, 70-kDa; TOR Serine-Threonine Kinases; TRPP Cation Channels | 2015 |
Efficacy and Safety of Abemaciclib, an Inhibitor of CDK4 and CDK6, for Patients with Breast Cancer, Non-Small Cell Lung Cancer, and Other Solid Tumors.
Topics: Aminopyridines; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 6; Disease Models, Animal; Drug Monitoring; Female; Humans; Lung Neoplasms; Male; Mice; Molecular Targeted Therapy; Neoplasm Metastasis; Neoplasm Staging; Neoplasms; Tomography, X-Ray Computed; Treatment Outcome; Xenograft Model Antitumor Assays | 2016 |
Lorlatinib Is Active in Drug-Resistant NSCLC.
Topics: Aminopyridines; Anaplastic Lymphoma Kinase; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase I as Topic; Drug Resistance, Neoplasm; Humans; Lactams; Lactams, Macrocyclic; Lung Neoplasms; Molecular Targeted Therapy; Mutation; Protein Kinase Inhibitors; Pyrazoles; Receptor Protein-Tyrosine Kinases; Treatment Outcome | 2016 |
Molecular Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in ALK-Rearranged Lung Cancer.
Topics: Aminopyridines; Anaplastic Lymphoma Kinase; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Cell Survival; Drug Resistance, Neoplasm; Humans; Lactams; Lactams, Macrocyclic; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Pyrazoles; Pyrimidines; Receptor Protein-Tyrosine Kinases; Sulfones | 2016 |
Blockade efficacy of MEK/ERK-dependent autophagy enhances PI3K/Akt inhibitor NVP-BKM120's therapeutic effectiveness in lung cancer cells.
Topics: Aminopyridines; Animals; Antineoplastic Agents; Autophagy; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Chloroquine; Enzyme Inhibitors; Humans; Lung Neoplasms; MAP Kinase Signaling System; Mice; Morpholines; Phosphoinositide-3 Kinase Inhibitors; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Xenograft Model Antitumor Assays | 2016 |
Targeting CXCR4 and FAK reverses doxorubicin resistance and suppresses invasion in non-small cell lung carcinoma.
Topics: Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily B; Benzylamines; Blotting, Western; Carcinoma, Non-Small-Cell Lung; Doxorubicin; Drug Resistance, Neoplasm; Focal Adhesion Kinase 1; Gene Expression Profiling; Humans; Lung Neoplasms; Multidrug Resistance-Associated Proteins; Neoplasm Invasiveness; Quinolones; Real-Time Polymerase Chain Reaction; Receptors, CXCR4; Sulfones; Transcriptome | 2017 |
Dual occurrence of ALK G1202R solvent front mutation and small cell lung cancer transformation as resistance mechanisms to second generation ALK inhibitors without prior exposure to crizotinib. Pitfall of solely relying on liquid re-biopsy?
Topics: Adult; Aged; Aminopyridines; Anaplastic Lymphoma Kinase; Carcinoma, Non-Small-Cell Lung; Cell Transformation, Neoplastic; Crizotinib; Disease Progression; Drug Resistance, Neoplasm; Fatal Outcome; Female; Humans; Lactams; Lactams, Macrocyclic; Liquid Biopsy; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplastic Cells, Circulating; Protein Kinase Inhibitors; Pyrazoles; Pyridines; Receptor Protein-Tyrosine Kinases; Retinoblastoma Binding Proteins; Small Cell Lung Carcinoma; Ubiquitin-Protein Ligases | 2017 |
The combination of RAD001 and NVP-BKM120 synergistically inhibits the growth of lung cancer in vitro and in vivo.
Topics: Aminopyridines; Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Culture Media, Serum-Free; Drug Synergism; Everolimus; G1 Phase; Gene Expression Regulation, Neoplastic; Humans; Immunosuppressive Agents; Lung Neoplasms; Male; Mice; Mice, Nude; Morpholines; Neoplasm Proteins; Phosphoinositide-3 Kinase Inhibitors; Phosphorylation; Protein Kinase Inhibitors; Protein Processing, Post-Translational; Proto-Oncogene Proteins c-akt; Recombinant Fusion Proteins; Signal Transduction; Sirolimus; TOR Serine-Threonine Kinases; Tumor Stem Cell Assay; Xenograft Model Antitumor Assays | 2012 |
Higher levels of c-Met expression and phosphorylation identify cell lines with increased sensitivity to AMG-458, a novel selective c-Met inhibitor with radiosensitizing effects.
Topics: Aminopyridines; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Survival; Drug Screening Assays, Antitumor; Humans; Lung Neoplasms; Neoplasm Proteins; Phosphorylation; Proto-Oncogene Proteins c-met; Pyrazoles; Radiation Tolerance; Radiation-Sensitizing Agents | 2012 |
Combined therapy with mutant-selective EGFR inhibitor and Met kinase inhibitor for overcoming erlotinib resistance in EGFR-mutant lung cancer.
Topics: Acrylamides; Aminopyridines; Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gene Amplification; Hepatocyte Growth Factor; Humans; Lung Neoplasms; Mice; Mice, SCID; Microvessels; Mutation; Phosphorylation; Piperazines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-met; Pyrimidines; Quinazolines; Xenograft Model Antitumor Assays | 2012 |